In his current role, he is responsible for strategic business development, software product development and services delivery for the pharma, food, consumer good, specialty & agrochemical industries.
Sean is a leading figure in the development and adoption of mechanistic model-based tools for increasing R&D efficiency and managing risk in areas ranging from clinical trials to tech transfer and operations. He is the driver behind QbD 2.0, which focuses on improving the efficiency of QbD by reintroducing the “sound science” element of the original QbD definition.
He is one of the founders of the Systems-based Pharmaceutics Alliance with Eli Lilly, GSK, Pfizer and Roche. This Alliance is developing and promoting a holistic approach to the development and optimization of drug formulations, drug manufacture processes and drug delivery
Sean is the lead for the £20.4m ADDoPT “Digital Design” Project with AZ, BMS, GSK & Pfizer, Britest, Perceptive Engineering, CCDC, STFC Hartree, U. Leeds, U. Cambridge and U. Strathclyde.
In addition, he is a board member of CMAC, the Centre for Continuous Manufacturing and Crystallisation at Strathclyde University. Other notable involvements with academia include C-SOPS and RCPE.
Sean is a Chemical Engineer with an MSc in Chemical Engineering and a PhD in crystallization from Delft University of Technology and an Executive MBA from Imperial College London.